Foley Hoag Advises Lead Investor in $36M Financing Round for TransMedics, Inc.

November 30, 2012

Foley Hoag LLP represented Abrams Capital in its $36 million investment in TransMedics, Inc., the global leader in organ preservation technology.

Abrams Capital is a Boston-based investment firm founded in 1999 that currently manages $5.7 billion. The firm’s investment strategy is opportunistic and follows a fundamental, value-oriented approach. The firm and its affiliates have acquired and liquidated profitable investments across a wide spectrum of investment types, investment strategies, market sectors, market cycles and industries. The investment in TransMedics will further the company’s mission of extending the life saving benefits of organ transplantation to patients suffering from end-stage organ failure through their Organ Care System (OCS™) Heart and Lung devices, which maintain donor organs in a near-physiologic and functioning condition from donor to transplant recipient.

The Foley Hoag team that advised Abrams Capital on the transaction included Mark Haddad and Amanda Vendig. The investment was supported by existing investors Flagship Ventures, Hercules Technology Growth Capital and Kleiner Perkins Caufield & Byers.